1R33CA225539-01 (R33) ApplID: 9492281 | |||
---|---|---|---|
Title | An integrated therapeutic T cell receptor screening platform for adoptive cell therapy in cancer | ||
Institution | UNIVERSITY OF TEXAS, AUSTIN, AUSTIN, TX | ||
Principal Investigator | JIANG, NING | NCI Program Director | Ossandon |
Cancer Activity | Technology Development | Division | DCTD |
Funded Amount | $396,959 | Project Dates | 04/04/2018 - 03/31/2021 |
Fiscal Year | 2018 | Project Type | Grant |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Cancer (100.0%) | N/A | ||
Research Type | |||
Technology Development and/or Marker Discovery Systemic Therapies - Discovery and Development |
|||
Abstract | |||
Abstract Recent successes of T cell receptor based adoptive cell transfer therapy have generated new excitement about this therapeutic approach. However, lacking a high-throughput method of screening of naturally occurring high- affinity therapeutic T cell receptors (TCRs) has put a limit on how widely this approach can be applied to different kinds of cancers and a large range of patients. In this study, we propose to develop an integrated platform that on one hand drastically speeds up the identification and test of therapeutic TCRs and on the other hand, profiles common cancer antigens and HLAs expressed in tumor sample at single cell level. We name it Magic-HAT for Matching antigen identification in cancer with High-Affinity TCRs. The success of this project breaks the bottleneck of identifying and testing naturally occurring therapeutic high-affinity TCRs in adoptive cell transfer therapy setting for a large panel of cancer antigen epitopes. It enables a new capability on using combination of TCRs in TCR-redirected T cells for adoptive cell transfer therapy in cancer." |